International Stem Cell Corporation Reports Q2 2026 Financial Results with Increased Sales but Continued Losses

International Stem Cell Corporation (ISCO) reported its financial results for the second quarter and first half of 2026, revealing a modest increase in product sales but continued net losses. For the three months ended June 30, 2026, ISCO generated $2.675 million in product sales, a 9% increase from $2.447 million in the same period last year. For the six months, total product sales reached $4.990 million, up from $4.576 million in 2025. Despite this growth, the company reported a net loss of $71,000 for the second quarter, compared to a net income of $129,000 in the prior year, and a net loss of $291,000 for the first half of 2026, compared to a loss of $127,000 in 2025.

The increase in revenue was primarily driven by higher sales in the biomedical market segment, particularly from media products, which saw a $410,000 increase, although this was partially offset by a decrease in cell sales. The cost of sales also rose significantly, increasing by 31% to $1.217 million in the second quarter, which contributed to a decline in profit margins. General and administrative expenses rose by 17% to $1.062 million, largely due to increased legal and consulting costs related to strategic activities and an impairment charge for abandoned patents.

In terms of operational metrics, ISCO's cash position improved slightly, with cash at the end of June 2026 totaling $1.089 million, compared to $993,000 at the end of 2025. The company continues to face challenges, including an accumulated deficit of approximately $111.4 million and ongoing negative cash flows from operations. The company has indicated that it will need to secure additional financing to sustain its operations and fund its research and development programs, as it currently does not generate revenue from its therapeutic product candidates.

Strategically, ISCO is focused on advancing its therapeutic product development, particularly in the areas of Parkinson's disease, traumatic brain injury, and stroke, utilizing its proprietary human parthenogenetic stem cells. The company has also announced plans to sell its subsidiary Lifeline Cell Technology, LLC, to American Type Culture Collection, Inc. for $25 million, which could provide a significant influx of cash to support its ongoing operations and development efforts. The transaction is subject to adjustments based on working capital and is expected to close soon.

Looking ahead, ISCO's management has expressed the need for substantial additional capital to continue its operations and develop its product pipeline. The company is exploring various financing options, including equity and debt financing, as well as potential collaborative research arrangements. However, there remains substantial doubt about the company's ability to continue as a going concern without securing additional funding.